Noxopharm Limited

Equities

NOX

AU000000NOX9

Pharmaceuticals

Market Closed - Australian S.E. 01:10:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.067 AUD +3.08% Intraday chart for Noxopharm Limited -5.63% -5.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive MT
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Noxopharm Extends Strategic Partnership with Hudson Institute of Medical Research MT
Noxopharm Receives AU$6.1 Million R&D tax Rebate; Shares Up 8% MT
Concerns of Further US Monetary Tightening Push Australian Shares to Nearly 11-Month Low MT
US FDA Grants Orphan Drug Status to Noxopharm's Pancreatic Cancer Drug; Shares Surge 73% MT
Noxopharm Validates Efficacy of Cancer Treatment in Animal Study; Shares Rally 13% MT
Noxopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
NobleOak Life Secures Approval from Financial Services Regulator for Reporting Standards MT
Noxopharm Limited Announces Change of Registered Office and Principal Place of Business CI
Study Finds Noxopharm's New SOF-XX Drug Reduces Inflammation MT
Noxopharm's NOXO Options to Expire June 18; Shares Down 17% MT
Noxopharm to Discontinue Veyonda Trials; to Focus on Chroma, Sofra Platforms; Shares Plummet 41% MT
Noxopharm to Develop Vaccine Enhancer; Shares Rise 3% MT
Noxopharm Limited Announces Novel mRNA Vaccine Enhancer CI
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Noxopharm Limited to Present Sofra Study at Lupus 2023 Conference CI
NobleOak Life to Release Shares from Voluntary Escrow MT
Noxopharm Advances to the Efficacy Portion of its Phase 2 Prostate Cancer Trial MT
Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial CI
Noxopharm's Strategic Partner Secures Grant Funding from the Australian Government MT
Noxopharm Receives Innovation Connections Grant; Shares Fall 5% MT
Noxopharm Limited Announces Award of Federal Innovation Connections Grant CI
Noxopharm Advances Phase 1 Cancer Drug Trial Following Safety Clearance MT
Noxopharm Validates Safety of Drug Candidate in Phase 1 Cancer Trial MT
Chart Noxopharm Limited
More charts
Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.
More about the company
  1. Stock
  2. Equities
  3. Stock Noxopharm Limited - Australian S.E.
  4. News Noxopharm Limited
  5. Noxopharm : Confirms Combination of Veyonda with LuPSMA Therapy Leads to Prostate Cancer Regression